CBER's research funding

WASHINGTON - The lack of investment in research at FDA's Center for Biologics Evaluation and Research (CBER) is a danger to the public health and the well being of the biotechnology industry, according to a report released last week by a review panel of the FDA's Science Board.

The report, commissioned by CBER Director Kathryn Zoon, was compiled by a committee that included 26 scientists from